Juan Pablo Hernández-Ovalle

Dr. Juan Pablo Hernández-Ovalle


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Travel Medicine and Infectious Disease
Verified
Journal Article
Open access
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
AAAbdulaziz Alhazmi
Abdulaziz Alhazmi
AKABRAHAM KATIME
ABRAHAM KATIME
AHAhneez Abdul Hameed
Ahneez Abdul Hameed
AMAlejandra Morales
Alejandra Morales
ESEsgitm Slamvi
Esgitm Slamvi

5 January 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
Shriyansh SrivastavaShriyansh Srivastava
Shriyansh Srivastava
NJNandani Jayaswal
Nandani Jayaswal
PGPranav Gupta
Pranav Gupta
SSSathvik Belagodu Sridhar
Sathvik Belagodu Sridhar
PJPooja Jaiswal
Pooja Jaiswal
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Yellow fever, a mosquito-borne viral hemorrhagic disease, remains a significant public health concern in endemic regions of Africa and South America. The development of the yellow fever vaccine marked a milestone in virology and immunization. In the 1930s, Max Theiler created the 17D live-attenuated vaccine, a breakthrough that has achieved global recognition and continues to underpin prevention strategies. This review outlines the historical evolution of the yellow fever vaccine, highlighting pivotal scientific advances, technological innovations, and global eradication initiatives. It examines the current landscape of immunization, focusing on the World Health Organization’s Eliminate Yellow Fever Epidemics (EYE) strategy, ongoing efforts to address vaccine supply constraints, and persistent surveillance gaps. Future directions in vaccine development, including next-generation platforms and improved delivery systems, are also discussed, alongside the need for sustained research investment and international collaboration. As yellow fever emerges in previously non-endemic areas due to climate change and globalization, strengthening vaccination programs remains critical to preventing outbreaks and ensuring effective disease control.

9 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Shriyansh SrivastavaShriyansh Srivastava
Shriyansh Srivastava
NJNandani Jayaswal
Nandani Jayaswal
PGPranav Gupta
Pranav Gupta
SSSathvik Belagodu Sridhar
Sathvik Belagodu Sridhar
PJPooja Jaiswal
Pooja Jaiswal
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Yellow fever, a viral hemorrhagic disease transmitted by mosquitoes, poses a significant public health issue in regions of Africa and South America where it is prevalent. Researchers believe that the development of the yellow fever vaccine was a significant advancement in virology and immunization. In the 1930s, Max Theiler developed the 17D live-attenuated vaccine, which has since gained global recognition and continues to play a vital role in disease prevention. This review traces the evolution of the yellow fever vaccine, highlighting key scientific breakthroughs, technological advances, and global eradication initiatives. It also examines the current state of yellow fever immunization, with a focus on the World Health Organization's Eliminate yellow fever Epidemics (EYE) strategy, ongoing efforts to resolve vaccine supply issues, and gaps in surveillance systems. Furthermore, the article explores future directions in vaccine development, including next-generation platforms and enhanced delivery methods, and emphasizes the importance of sustained research funding and international collaboration. As yellow fever reemerges in previously non-endemic areas due to climate change and globalization, strengthening vaccination programs remains crucial for effective disease prevention and control of outbreaks.

25 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SVSandra Valencia
Sandra Valencia
Martha ZuluagaMartha Zuluaga
Martha Zuluaga
MBMaría Camila Bernal
María Camila Bernal
JHJuan Pablo Hernández-Ovalle
Juan Pablo Hernández-Ovalle
AUAna Lorena Uribe
Ana Lorena Uribe
Human breast milk is a dynamic biological fluid essential for infant growth, immune regulation, and early metabolic development. Maternal diabetes mellitus can alter its molecular composition, potentially impacting its nutritional value and the infant’s future metabolic health. This study compared the metabolomic profiles of breast milk from healthy versus diabetic women using untargeted metabolomics with GC/MS-QTOF on samples from normoglycemic and type 2 diabetic cohorts. Supervised multivariate statistics and metabolic pathway analysis identified discriminant metabolites and clarified biological relevance. Distinct metabolomic signatures were found: milk from diabetic mothers showed changes in short-chain fatty acids, amino acid derivatives, carbohydrates, and lipid-related molecules, with alterations in pathways such as energy metabolism, oxidative stress, and microbial co-metabolism. These specific changes in the milk metabolome may influence infant metabolic programming and highlight the need for personalized nutritional approaches for mothers with metabolic disorders, supporting metabolomics as a tool to monitor breast milk quality.